Literature DB >> 7373086

Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus.

F G Hayden, W J Hall, R G Douglas.   

Abstract

The effect of small-particle aerosol therapy with amantadine was assessed in a randomized, double-blind study of 20 patients with naturally acquired influenza A virus infection. Aerosol treatments of 20 min with either distilled water or with amantadine hydrochloride (1.0 g/100 ml of distilled water) were given three times a day for four days. The amantadine-treated patients experienced a significantly more rapid resolution of clinical signs and symptoms when compared with placebo-treated patients. The resolution of fever was similar for both groups. Aerosol delivery of amantadine did not affect the frequency of viral isolation from upper respiratory tract secretions but was associated with a trend toward reduced quantity of viral shedding. Serial pulmonary function tests found no important differences between the groups. Amantadine-treated patients experienced a greater frequency of mild local side effects (rhinorrhea, nasal irritation) during aerosol exposures, but aerosol treatments did not cause any apparent decline in pulmonary function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373086     DOI: 10.1093/infdis/141.5.535

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Amantadine and rimantadine for influenza A in adults.

Authors:  T Jefferson; V Demicheli; C Di Pietrantonj; D Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Amantadine for influenza A.

Authors:  K G Nicholson; M J Wiselka
Journal:  BMJ       Date:  1991-02-23

4.  A pharmacoeconomic model for the treatment of influenza.

Authors:  J A Mauskopf; S C Cates; A D Griffin
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

5.  Changing virulence of influenza A viruses.

Authors:  R G Douglas; W J Hall; R F Betts
Journal:  Trans Am Clin Climatol Assoc       Date:  1982

6.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Viral respiratory diseases: vaccines and antivirals.

Authors:  E H Lennette
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

Review 8.  Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis.

Authors:  K G Nicholson
Journal:  Lancet       Date:  1984-09-15       Impact factor: 79.321

9.  Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice.

Authors:  P R Wyde; S Z Wilson; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Comparative activity of amantadine and ribavirin against influenza virus in vitro: possible clinical relevance.

Authors:  M J Browne; M Y Moss; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.